These guys are long way from the market, but worth noting as competition . . .
>>LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Dec. 8, 2003--BioSante Pharmaceuticals, Inc. (Amex:BPA - News) today announced that it presented data on its new nanoparticulate-based technology for the delivery of insulin at the Pharmaceutical Education Associates symposium on Inhalation Drug Delivery in Princeton, New Jersey, last week.
"Among efficacy studies that evaluate various inhalable insulin formulations and are relevant for comparison, our formulation demonstrated the highest bioavailability using the smallest dose," said Dr. Tulin Morcol, associate director of drug delivery and related technologies for BioSante. The company is also developing promising new systems for the administration of insulin in oral tablet or capsule form, as well as via long-acting injection.
The presentation summarized positive results from a series of preclinical studies of the company's BioAir(TM) calcium phosphate nanoparticulate (CAP) delivery system for inhalable insulin. The studies showed the BioSante formulation significantly increased the systemic residence time and duration of action of the insulin, increasing the amount of insulin that became available through the bloodstream (bioavailability) 1.8 times over that of injected insulin.
"We are pleased with the progress we have made toward the development of important new delivery methods for insulin and other therapies," said Stephen M. Simes, president and chief executive officer of BioSante. "The development of an inhalable insulin would represent an easy, pain-free alternative to insulin injections, allowing diabetics to live more normal, comfortable lives." <<
snip
Cheers, Tuck |
